Evidence-Based Complementary and Alternative Medicine / 2014 / Article / Tab 4

Research Article

A Metabonomics Profiling Study on Phlegm Syndrome and Blood-Stasis Syndrome in Coronary Heart Disease Patients Using Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry

Table 4

Plasma metabolites for discriminating CHD patients from healthy controls.

ModeRT Mass Metabolite VIP aFold

EIS+6.21542.28Cortolone-3-glucuronide1.75 −25.59
5.74431.2117-Phenoxy trinor PGF2 ethyl amide1.74 −25.32
5.71562.37Cholesterol glucuronide1.74 −25.35
5.03362.22Cortisol1.73 −24.65
7.52890.51Dipalmitoyl phosphatidylinositol 3-phosphate1.73 −25.53
15.91370.24TXB21.73 −24.54
13.41393.3PGH2-EA1.71 −25.08
15.90298.1813,14-Dihydro-15-keto-tetranor PGE21.70 −25.84
15.90372.25TXB11.70 −26.76
11.98338.1718-Carboxy dinor leukotriene B41.70 −24.83
8.98413.2615-Keto-17-phenyl trinor Prostaglandin F2α ethyl amide1.66 −24.57
14.52510.28Leukotriene D4 methyl ester1.65 −22.56
6.71427.2717-Phenyl trinor prostaglandin F2α Cyclopropyl amide1.61 −24.27
16.05348.23 PGA2 methyl ester1.59 −22.23
5.77472.24Chenodeoxycholic acid 3-sulfate1.50 −23.70

EIS1.03 244.07 Uridine1.98 −0.72
16.61 348.23 PGA2 methyl ester1.98 3.52
1.02 136.04 Hypoxanthine1.90 −1.84
1.03 192.03 Citric acid1.89 2.12
3.81 204.09 L-Tryptophan1.88 −1.01
3.81 324.03 Uridine monophosphate (UMP)1.81 −1.98
2.00 165.08 L-Phenylalanine1.61 −1.30
4.66 282.11 2-Aminoadenosine1.56 −2.41
13.16 625.30 Leukotriene C41.55 −2.20
16.62 302.22 EPA1.55 −2.47
16.88 336.23 LTB41.53 4.50
1.91 116.05 2-Keto valeric acid1.51 −2.05

Fold = log2(average peak intensity of CHD group/average peak intensity of healthy group), “−” represented downregulated compared to healthy group, and “+” represented upregulated compared to healthy group.